Q3 2023 Cutera Inc Earnings Call Transcript
The entire industry is facing the same macro pressures. For Cutera, our business has migrated into more economically sensitive practices over the past few years, which creates more exposure to discretionary spending.
The challenges we've experienced some service and reliability has dampened our ability to grow and will likely continue to do so during 2024.
I'll speak later to how we're addressing these issues but a reasonable expectation is that it will take some period of time after that improvement for us to win back trust. We are being patient, putting the customer first and adjusting our cost structure, as we wait for the macro and company-specific headwinds to pass.
Additionally, AviClear, and our entire skin suite portfolio, including excel V+ and Secret, provide us an opportunity to migrate our business mix back to core dermatology practices over time.
We finished Q3 with approximately $180 million of cash on the balance sheet, with Q3 cash burn modestly below Q1 and Q2 levels. We burned a little more cash in the quarter than
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |